InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.011 -0.249 (-95.77%)+
Announcement
Release
16 Jun 2026 8:53AM
Price at Release
$0.260
Full Release
download
Summary
On June 16, 2026, Cynata Therapeutics Limited requested a voluntary suspension of its securities from quotation on the Australian Securities Exchange. This action is in accordance with ASX Listing Rule 17.2 and is pending material announcements related to the results of its Phase 3 Osteoarthritis Trial and Phase 2 Graft versus Host Disease Trial. Cynata expects to release these results by June 20, 2026. The company, which focuses on developing therapies based on its proprietary Cymerus™ stem cell technology, stated that it is unaware of any reasons that the suspension should not be granted.
Key Points
  • Cynata Therapeutics requested a voluntary suspension of its quoted securities.
  • The voluntary suspension is pending the announcement of results from clinical trials.
  • Cynata expects to release trial results by June 20, 2026.
  • The company is not aware of any reason why the suspension should not be granted.
  • Cynata is an Australian stem cell and regenerative medicine company.
  • Cynata is developing therapies based on their proprietary Cymerus™ stem cell technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.